Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement
- Conditions
- Solid Tumors
- Registration Number
- NCT00882180
- Lead Sponsor
- Alnylam Pharmaceuticals
- Brief Summary
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 41
- Patients must have histologically or cytologically confirmed advanced solid tumors that have recurred or progressed following standard therapy, or that have not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
- Patient has measurable tumor in the liver
- At least 28 days have elapsed since the patient's prior systemic therapy, radiotherapy, or any major surgery
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
- Patient has adequate hematologic, liver, and renal function
- Patient is seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV)
- Patient has a life expectancy > 12 weeks
- Patient is receiving full-dose (therapeutic) anticoagulation therapy and/or aspirin > 325 mg/day or other platelet inhibitory agents
- Patient has clinically significant cardiovascular disease or uncontrolled serious cardiac arrythmia
- Patient has known active brain or leptomeningeal metastases
- Patient has clinically significant cerebrovascular disease
- Patient has a seizure disorder not controlled on medication
- Patient has a known or suspected viral, parasitic or fungal infection
- Patient previously experienced a severe reaction to a liposomal product
- Patient has a known hypersensitivity to lipid products
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety and Tolerability of intravenous ALN-VSP02 up to 16 weeks (4 cycles)
- Secondary Outcome Measures
Name Time Method Plasma and urine PK of ALN-VSP02 8 weeks (two cycles) Assess preliminary evidence of antitumor/antiangiogenic activity Up to 16 weeks (4 cycles)
Trial Locations
- Locations (10)
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Center
🇺🇸Detroit, Michigan, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Catalonia, Spain
Hospital Virgen del Rocio
🇪🇸Seville, Andalucia, Spain
TGen Clinical Research Service at Scottsdale Healthcare
🇺🇸Scottsdale, Arizona, United States
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain